Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’View Video
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin AmericaView Video

Latest Share Chat

Norway's committee recommends dropping AstraZeneca, J&J jabs

Mon, 10th May 2021 12:08

(Alliance News) - An expert committee set up by Norway's government to evaluate AstraZeneca PLC's and Johnson & Johnson's Covid-19 vaccines said on Monday that both should be abandoned over risks of rare but serious side effects.

In order to avoid a slowdown of the vaccine rollout the committee recommended that the two jabs should be made available for people on a voluntary basis.

The committee's head Lars Vorland said they did "not recommend the use of adenoviral vector vaccines in the national immunisation programme", as he handed in their report.

"This is of course because of the serious side effects" observed in a small proportion of people who have been injected with these vaccines, Vorland added. 

Health Minister Bent Hoie has not yet made the government's position on the use of the vaccines known. 

From the 134,000 injections of AstraZeneca's vaccine administered in Norway up until mid-March, five cases of severe thrombosis – three of them fatal – were reported in relatively young and previously healthy people. Another vaccine recipient died of a brain haemorrhage.

Norway suspended AstraZeneca's vaccine on March 11 while its rare but potentially serious side effects were studied in more detail. 

On April 15, Norwegian health authorities recommended dropping the jab from the Anglo-Swedish drugmaker, but the government chose to first set up a committee of experts to examine the risks associated with the AstraZeneca and Johnson & Johnson vaccines – which are both based on the same adenovirus technology.

The European Medicines Agency and the World Health Organization both recommend continued use of the vaccines, arguing that the benefits far outweigh  the associated risks.

US drugmaker Johnson & Johnson's vaccine has not yet been deployed in the country, but rare cases of thrombosis have been reported in the US. 

Neighbouring Denmark is the only country in Europe that has officially dropped AstraZeneca and Johnson & Johnson's vaccines, but many have restricted the use of AstraZeneca's to certain age groups.

source: AFP

Copyright 2021 Alliance News Limited. All Rights Reserved.

Related Shares

More News
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump...

25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth readi...

25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover ta...

25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln *

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.